Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Optimising cancer support for rural residents from a refugee background: changing models of access and care.

Australian journal of primary health·2026

Same author

Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial).

Haematologica·2026

Same author

Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia.

PloS one·2026

Same author

An abnormal increase in CD26(-)CD28(-) cytotoxic effector CD4 and CD8 T cell populations in patients with systemic lupus erythematosus.

International immunology·2024

Same author

The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.

Frontiers in immunology·2024

Same author

A study of generative large language model for medical research and healthcare.

NPJ digital medicine·2023

Search research articles

Related Experiment Videos

Bendamustine: a novel cytotoxic agent for hematologic malignancies.

Susan Blumel¹, Amy Goodrich, Cheryl Martin

¹University of Nebraska Medical Center, Omaha, USA. sblumel@unmc.edu.

Clinical Journal of Oncology Nursing

|October 10, 2008

Summary

Bendamustine hydrochloride is an effective treatment for hematologic malignancies with manageable side effects. Understanding its efficacy and safety profile is crucial for patient care and education.

Related Experiment Videos

Area of Science:

Oncology
Pharmacology

Background:

Hematologic malignancies require effective and well-tolerated treatments.
Bendamustine hydrochloride, a novel cytotoxic agent, combines alkylator and purine-like structures for a unique mechanism of action.
Bendamustine is approved for chronic lymphocytic leukemia (CLL) and investigated in trials for other cancers.

Purpose of the Study:

To review the efficacy and safety of bendamustine hydrochloride in treating hematologic malignancies.
To inform healthcare professionals, particularly nurses, about bendamustine's use, side effects, and management.

Main Methods:

Review of clinical trial data and published literature on bendamustine hydrochloride.
Analysis of efficacy, safety, and toxicity profiles from monotherapy and combination studies.

Main Results:

Bendamustine demonstrates promising clinical activity in hematologic malignancies.
Common nonhematologic side effects include nausea, fatigue, vomiting, fever, diarrhea, constipation, and headache.
Reversible myelosuppression is a reported toxicity.

Conclusions:

Bendamustine hydrochloride offers a manageable toxicity profile for patients with hematologic malignancies.
Educating patients and families on expected side effects and management strategies is vital for optimal care.
Nurses play a key role in patient education and managing bendamustine-related toxicities.